Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 29, 2010
-
Jun 26, 2010- Study Findings Presented at American Diabetes Association's 70th Annual Scientific Sessions -
-
Jun 25, 2010- Study Results Presented at American Diabetes Association's 70th Annual Scientific Sessions -
-
Jun 17, 2010- First and only therapy to provide significant survival benefit in second-line metastatic hormone-refractory prostate cancer -
-
May 26, 2010- Alliance formed to advance cutting-edge research and foster collaboration between academia and industry -
-
May 5, 2010- Sanofi-aventis Supports Consortium's Activities to Fund Promising Early-Stage Life Sciences Companies -
-
Apr 29, 2010
-
Apr 12, 2010The licensed technology was developed by the NMRC with the help of the University of Colorado
-
Apr 1, 2010Interactive Exhibit Unveiled at New Jersey's Liberty Science Center as it Embarks on Three-Year, 12-City Tour
-
Mar 11, 2010Chattem Becomes the U.S. Consumer Healthcare Platform for sanofi-aventis
-
Mar 3, 2010- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy -
-
Mar 3, 2010The Coalition to Prevent DVT Sends Awareness into Motion with an Educational Program Focusing on Preventative Care Through Movement
-
Feb 23, 2010New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months
-
Jan 20, 2010"AFib Support Team" Offers Insights on Comprehensive Approach to Management of Serious Heart Condition
-
Dec 21, 2009Fluzone® High-Dose (Influenza Virus Vaccine) strengthens immune response in the 65+ population, an age group that suffers disproportionately from influenza and its complications
-
Dec 21, 2009-- Combination Strengthens sanofi-aventis' Strategy to Accelerate Growth Through Innovation, Geographic Expansion and External Growth
-
Dec 15, 2009Novel vaccine approach tested against one of the most common causes of hospital-acquired infection in Europe and North America
-
Dec 11, 2009- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -
-
Nov 11, 2009Final data confirm immunogenicity, safety profile
-
Nov 2, 2009The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated
-
Oct 16, 2009- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -
-
Oct 14, 2009The first clinical trial data from America’s youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated
-
Oct 6, 2009Taking Control of Your Diabetes (TCOYD) Calls on Marketing Leaders and Creative Minds to "Start Taking Action Now for Diabetes"
-
Oct 1, 2009Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years
-
Oct 1, 2009Women may delay treatment or seek injectable procedures
-
Sep 21, 2009Company has now committed to produce 75.3 million doses of vaccine for the U.S. government
-
Sep 16, 2009"AF Stat(TM) Call to Action for Atrial Fibrillation" Report Cites Limited Understanding, Disconnected Dialogue and Uncoordinated Care as Key Barriers to Improved Outcomes
-
Sep 15, 2009Influenza A (H1N1) 2009 Monovalent Vaccine licensure a key U.S. milestone in preparing for pandemic response this Fall
-
Aug 24, 2009Approval Includes Use in Patients Two Years and Older with Seasonal Nasal Allergies Which Affect Forty Percent of Children in the U.S.
-
Aug 20, 2009New York City Proclaims August 20, 2009 “Pertussis Awareness Day”
-
Aug 17, 2009- Prophylaxis with Lovenox® (enoxaparin sodium injection) offered a cost reduction per discharge -
-
Aug 7, 2009Company responds to FDA recommendation for influenza virus strain change supplement